Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer

Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer
An upcoming Phase 1b/2 trial will evaluate Syndax Pharmaceuticals' investigational therapy entinostat in combination with Genentech's Tecentriq (atezolizumab) in women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have received one previous line of therapy. The trial is part of a new clinical collaboration between the two companies. It will be conducted by Genentech, and will be inserted into Roche’s MORPHEUS cancer development platform ­that aims to develop immunotherapy combination treatments more rapidly and efficiently. Genentech is a member of the Roche group. Entinostat is an oral small molecule that inhibits the function of class I histone deacetylases (HDAC) — it prevents HDACs from adding acetyl molecules to certain proteins, a modification that determines protein activity and function. This allows entinostat to block immunosuppressive cells — like myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs) — enhancing the immune system's ability to recognize and kill tumor cells. Tecentriq is a monoclonal antibody that binds PD-L1, a protein that helps cancers evade the immune system's response. When the PD-L1 protein, produced by cancer cells, binds its receptor PD-1, a kind of "off switch" is triggered in immune cells, impairing them from seeing cancer cells as malignant. Drugs targeting either one of these proteins — PD-1 or PD-L1 — block this interactio
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.